Novo Nordisk, Wegovy
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...
China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...
The new study, paid for by Novo Nordisk, included 82 children with a mean age of 10 and a baseline weight of about 155 ...
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1]. The trial investigated ...
At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...
One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker ...
Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to ...
Lawsuit is part of a nationwide strategy by Novo Nordisk to protect its trademark and profits from its blockbuster GLP-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback